The role of CD47 in non-neoplastic diseases

The role of CD47 in non-neoplastic diseases

CD47 is a 50 kDa five-spanning membrane receptor that plays a crucial role in multiple cellular processes, including myeloid cell activation, neutrophils transmigration, vascular remodeling, leukocyte adhesion and trans-endothelial migration. Recent studies have revealed that CD47 is a highly expres...

Full description

Bibliographic Details
Main Authors:	Chao Wang, Ying Feng, Deepali Patel, Hongwei Xie, Yaqing Lv, Hai Zhao
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	Heliyon
Subjects:	CD47 SIRPα Immune modulation Immunotherapies Atherosclerosis Neurological disorders
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844023101137

Similar Items

CD47 as a promising therapeutic target in oncology
by: Hai Zhao, et al.
Published: (2022-08-01)

Cancer Therapy Targeting CD47/SIRPα
by: Nazli Dizman, et al.
Published: (2021-12-01)

Research Progress on Relation Between CD47 and Immunotherapy on Lymphoma
by: LUO Yiyang, et al.
Published: (2021-08-01)

Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01)

Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
by: Abdullahi Alausa, et al.
Published: (2022-07-01)

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
by: Haiqin Liao, et al.
Published: (2022-04-01)

Tolerating CD47
by: Jeffrey S. Isenberg, et al.
Published: (2024-02-01)

Targeting CD47 as a therapeutic strategy: A common bridge in the therapy of COVID-19-related cancers
by: Milad Zandi, et al.
Published: (2023-07-01)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
by: Can Chen, et al.
Published: (2022-07-01)

The landscape overview of CD47-based immunotherapy for hematological malignancies
by: Hua Yang, et al.
Published: (2023-02-01)

CD47–SIRPα-targeted therapeutics: status and prospects
by: R. Maute, et al.
Published: (2022-03-01)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
by: Wenting Zhang, et al.
Published: (2020-01-01)

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
by: Amy Xiao, et al.
Published: (2022-11-01)

Regulation of CD47 expression on CD14+ monocytes by interferon-α in PBC patients
by: Xi Su, et al.
Published: (2023-12-01)

Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation
by: Zhiqiang Li, et al.
Published: (2021-08-01)

CD47-SIRPα axis in cancer therapy: Precise delivery of CD47-targeted therapeutics and design of anti-phagocytic drug delivery systems
by: Junqiao Zhu, et al.
Published: (2022-09-01)

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
by: Erik Voets, et al.
Published: (2019-12-01)

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
by: Tailong Qu, et al.
Published: (2022-04-01)

High-affinity decoy protein, nFD164, with an inactive Fc region as a potential therapeutic drug targeting CD47
by: Zhihong Wang, et al.
Published: (2023-06-01)

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
by: Leonie M. Behrens, et al.
Published: (2022-07-01)

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal
by: Jifeng Yu, et al.
Published: (2022-11-01)

CD47 in the Brain and Neurodegeneration: An Update on the Role in Neuroinflammatory Pathways
by: Seyed Mohammad Gheibihayat, et al.
Published: (2021-06-01)

An antitumor peptide RS17‐targeted CD47, design, synthesis, and antitumor activity
by: Xinmin Wang, et al.
Published: (2021-03-01)

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)
by: Jifeng Yu, et al.
Published: (2022-08-01)

Is CD47 an innate immune checkpoint for tumor evasion?
by: Xiaojuan Liu, et al.
Published: (2017-01-01)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
by: Pengcheng Zhao, et al.
Published: (2024-01-01)

Molecular mechanics and dynamics simulation of CD-47/SIRPα blockade study: A computational study on overcoming immunotherapeutic resistance in pancreatic ductal adenocarcinoma
by: Oluwatosin A. Saibu, et al.
Published: (2023-11-01)

Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis
by: Xiao-Jing Chen, et al.
Published: (2024-01-01)

A New Serum Macrophage Checkpoint Biomarker for Innate Immunotherapy: Soluble Signal-Regulatory Protein Alpha (sSIRPα)
by: Yoanna V. Vladimirova, et al.
Published: (2022-07-01)

Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation
by: Emily C. Suter, et al.
Published: (2021-08-01)

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
by: Tracy C. Kuo, et al.
Published: (2020-11-01)

Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy
by: Bo Huang, et al.
Published: (2021-01-01)

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
by: Jason C. Andrechak, et al.
Published: (2022-04-01)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
by: Jinyang Hu, et al.
Published: (2020-11-01)

Membrane-Mediated Cooperative Interactions of CD47 and SIRP<i>α</i>
by: Long Li, et al.
Published: (2023-11-01)

Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells
by: Sukhbir Kaur, et al.
Published: (2024-03-01)

Anomalous Levels of CD47/Signal Regulatory Protein Alpha in the Hippocampus Lead to Excess Microglial Engulfment in Mouse Model of Perioperative Neurocognitive Disorders
by: Min Shui, et al.
Published: (2022-03-01)

Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas
by: Amanda R. Dancsok, et al.
Published: (2020-01-01)

Deletion of CD47 from Schwann cells and macrophages hastens myelin disruption/dismantling and scavenging in Schwann cells and augments myelin debris phagocytosis in macrophages
by: Miri Gitik, et al.
Published: (2023-10-01)

A SIRPα‐Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer
by: Yao Huang, et al.
Published: (2020-03-01)